title: How to ensure clinical trial sensitivity in psychotropic drug development: a case study.
authors.forename: Sebastián
authors.initials: S
authors.lastname: Videla
authors.forename: Mariano
authors.initials: M
authors.lastname: Sust
authors.forename: Anna
authors.initials: A
authors.lastname: Fresquet
authors.forename: Jesús
authors.initials: J
authors.lastname: Villoria
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D035061:Control Groups; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design / Q000706:statistics & numerical data*
chemical_list: D014151:Anti-Anxiety Agents; D015507:Drugs, Investigational; D010919:Placebos; D008140:Lorazepam